Last June, the Exscalate4cov consortium announced an important result in the fight against COVID-19.
From April, the project, supported by the European Commission, works to identify effective treatments against coronavirus. Exploiting the the CINECA, Barcelona supercomputing center, and Julich HPC resources, and researchers’ scientific competence, the project has already tested in silico about 400 000 molecules, including drugs which are already on the market or in clinical investigation including drugs. Among these drugs, 7000 compounds have been selected as promising molecules, 700 molecules have been deemed interesting during in vitro tests, and 100 molecules have shown an act by blocking the virus replication.
The most important outcome has been achieved with raloxifene, a drug already in commerce to treat osteoporosis in menopausal women, already tested during the in siliico and in vitro studies.
The last 27 October, the Italian Medicines Agency (AIFA) has approved the human clinical trials with the raloxifene to treat patients COVID-19 with mild symptoms. The test will be carried out in two different institutes, Spallanzani and Humanitas, on 450 patients.